ATE167675T1 - 4h-naphtho(1,2b-b)pyranderivate als antiproliferative mittel - Google Patents

4h-naphtho(1,2b-b)pyranderivate als antiproliferative mittel

Info

Publication number
ATE167675T1
ATE167675T1 AT93301156T AT93301156T ATE167675T1 AT E167675 T1 ATE167675 T1 AT E167675T1 AT 93301156 T AT93301156 T AT 93301156T AT 93301156 T AT93301156 T AT 93301156T AT E167675 T1 ATE167675 T1 AT E167675T1
Authority
AT
Austria
Prior art keywords
alkyl
optionally substituted
hydrogen
phenyl
cor
Prior art date
Application number
AT93301156T
Other languages
English (en)
Inventor
Michael Brunavs
Colin Peter Dell
Peter Thaddeus Gallagher
William Martin Owton
Colin William Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE167675T1 publication Critical patent/ATE167675T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT93301156T 1992-02-19 1993-02-17 4h-naphtho(1,2b-b)pyranderivate als antiproliferative mittel ATE167675T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929203497A GB9203497D0 (en) 1992-02-19 1992-02-19 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ATE167675T1 true ATE167675T1 (de) 1998-07-15

Family

ID=10710655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93301156T ATE167675T1 (de) 1992-02-19 1993-02-17 4h-naphtho(1,2b-b)pyranderivate als antiproliferative mittel

Country Status (23)

Country Link
US (3) US5378699A (de)
EP (1) EP0557075B1 (de)
JP (1) JPH061784A (de)
KR (1) KR100274103B1 (de)
CN (1) CN1038680C (de)
AT (1) ATE167675T1 (de)
AU (1) AU664412B2 (de)
CA (1) CA2089974A1 (de)
CZ (1) CZ21793A3 (de)
DE (1) DE69319262T2 (de)
DK (1) DK0557075T3 (de)
ES (1) ES2117097T3 (de)
FI (1) FI930719A7 (de)
GB (1) GB9203497D0 (de)
HU (1) HUT63844A (de)
IL (1) IL104739A (de)
MX (1) MX9300840A (de)
MY (1) MY109777A (de)
NO (1) NO301712B1 (de)
NZ (1) NZ245906A (de)
RU (1) RU2083572C1 (de)
TW (1) TW257760B (de)
ZA (1) ZA931097B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
US5925673A (en) * 1994-12-23 1999-07-20 Alcon Laboratories, Inc. Benzofurans and benzopyrans as cytoprotective agents
US5811453A (en) 1994-12-23 1998-09-22 Alcon Laboratories, Inc. Viscoelastic compositions and methods of use
JPH10273467A (ja) * 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
FR2796312B1 (fr) * 1999-07-16 2001-09-07 Atofina Catalyseur metallique supporte, sa preparation et ses applications dans la fabrication directe du peroxyde d'hydrogene
DE60333094D1 (de) * 2002-04-17 2010-08-05 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
DE102004032418A1 (de) * 2004-04-07 2005-10-27 Bayer Cropscience Ag Wirkstoffkombinationen mit insektiziden Eigenschaften
US10730885B1 (en) 2019-04-30 2020-08-04 King Saud University Coumarin derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243674A (en) * 1978-06-12 1981-01-06 Pfizer Inc. 9-Hydroxydibenzo[b,d]pyrans and intermediates therefore
US4931221A (en) * 1988-12-30 1990-06-05 Ppg Industries, Inc. Photochromic spiropyran compounds
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
US5281619A (en) * 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications

Also Published As

Publication number Publication date
DE69319262T2 (de) 1998-11-12
NO930559L (no) 1993-08-20
IL104739A0 (en) 1993-06-10
IL104739A (en) 1997-01-10
US5663375A (en) 1997-09-02
US5378699A (en) 1995-01-03
KR100274103B1 (ko) 2000-12-15
CA2089974A1 (en) 1993-08-20
MX9300840A (es) 1993-09-01
US5622987A (en) 1997-04-22
AU3309993A (en) 1993-08-26
EP0557075A1 (de) 1993-08-25
CZ21793A3 (en) 1994-02-16
FI930719A0 (fi) 1993-02-18
HU9300446D0 (en) 1993-05-28
CN1038680C (zh) 1998-06-10
ZA931097B (en) 1994-08-17
EP0557075B1 (de) 1998-06-24
FI930719A7 (fi) 1993-08-20
HUT63844A (en) 1993-10-28
AU664412B2 (en) 1995-11-16
NZ245906A (en) 1995-04-27
MY109777A (en) 1997-06-30
CN1076696A (zh) 1993-09-29
DK0557075T3 (da) 1998-12-14
NO301712B1 (no) 1997-12-01
DE69319262D1 (de) 1998-07-30
TW257760B (de) 1995-09-21
ES2117097T3 (es) 1998-08-01
KR930017887A (ko) 1993-09-20
JPH061784A (ja) 1994-01-11
GB9203497D0 (en) 1992-04-08
NO930559D0 (no) 1993-02-17
RU2083572C1 (ru) 1997-07-10

Similar Documents

Publication Publication Date Title
DE69319262D1 (de) 4H-Naphtho(1,2b-b)Pyranderivate als antiproliferative Mittel
ATE185792T1 (de) Stilbenderivate und diese enthaltende pharmazeutische zusammensetzungen
ATE174917T1 (de) Pyrazolo(1,5-a>pyrimidinderivate und sie enthaltende antiinflammatorische mittel
ATE161836T1 (de) 4-substituierte-2-deoxy-2,3-didehydro alpha-d- neuraminsäure antivirale derivate
FI941396L (fi) Koostumuksia biologisesti aktiivisen TGF-valvottua vapauttamista varten
BR0214277A (pt) Solvatos de paclitaxel
MX9203668A (es) Nucleosidos de pirimidina antivirales.
DE69015842D1 (de) Nicotinsäurederivate und diese enthaltende pharmazeutische Zusammensetzungen.
HUT62281A (en) Process for producing new naphto/1,2-b/pyran derivatives and pharmaceutical compositions comprising same as active ingredient
NO975666D0 (no) Pyrroldovater og medisinsk sammensetning
DE60023647D1 (de) Makrolide mit entzündungshemmender wirkung
ATE182587T1 (de) Derivate von 6-substituierten azyklischen pyrimidin-nukleosiden und diese als wirkstoff enthaltende antivirale mittel
DE69223736D1 (de) Acridine-1,8-Dionderivate als therapeutisches Mittel
ATE161531T1 (de) Acridine-1,8-dionderivate als therapeutisches mittel
DE69126469D1 (de) Pyrimidin-Nukleosid-Derivate und antivirale Mittel, die diese Derivate als aktiven Bestandteil enthalten
ATE274903T1 (de) Antivirale mittel
DK0388049T3 (da) Penciclovirderivater til behandling af hepatitis B infektioner
DE69024060D1 (de) Osteogenesis-stimulierende mittel.
ATE285240T1 (de) Verwendung von sulfoquinovosyldiacylglycerol derivativen als immunosuppresssiva
ATE129232T1 (de) 6,7-disubstituierte 2-aminotetraline als immunomodulatoren und pharmazeutische zusammensetzungen davon.
DE60039782D1 (de) Amidinophenylbrenztraubensäure-derivat
FI910511A0 (fi) Foerfarande foer framstaellning av substituerade b-diketoner.
DE69111530D1 (de) Pyridincarbonsäure-Amid-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
DK0779075T3 (da) Anvendelse af 3-alpha-hydroxy-5-alpha-androsta-16-en som lægemidler
ES1022953Y (es) Dispositivo limitador de carrera.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee